Le Lézard

Skyhawk Therapeutics Releases Twelve-Month cUHDRS Subcomponent Results from its Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease

Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, announces cUHDRS subcomponent data from the twelve-month ...
BMJ

Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson’s disease (MOST-ABLE study): protocol for a randomised, double-blind ...

Introduction Accumulating evidence suggests that glucagon-like peptide-1 (GLP-1) receptor agonists may have therapeutic effects against Parkinson’s disease (PD); however, clinical evidence has not yet ...
HDBuzz

Skyhawk Shares A Closer Look at SKY-0515 Data, Plus A Peek At Expanding US Trial Access

On June 30th, Skyhawk Therapeutics shared a press release with new twelve-month data from the ongoing Phase 1/2 trial of ...
The Lancet

Multiple sclerosis: emerging epidemiological trends and redefining the clinical course

bDanish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital-Rigshospitalet, Glostrup, Denmark cDepartment of Neurology and Center of Clinical Neuroscience, First Faculty ...